{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-118940","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.292656+00:00","generated_at":"2026-06-26T04:44:02.905173+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Phathom Pharmaceuticals appoints Frank Karbe to board of directors","bullets":["Frank Karbe appointed as Class II director effective April 25, 2022; will serve on audit and compensation committees.","Karbe previously served as President and CFO of Myovant Sciences, and EVP and CFO of Exelixis.","Received option to purchase 20,000 shares of common stock with three-year vesting, plus cash compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-118940","json":"https://secwatch.observer/filing/0001193125-22-118940.json","markdown":"https://secwatch.observer/filing/0001193125-22-118940.md","text":"https://secwatch.observer/filing/0001193125-22-118940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/0001193125-22-118940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/d622345d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:44:02.905173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c53638c33d","claim":"Frank Karbe was appointed as Director at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"On April 25, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Frank Karbe to the Board as a Class II director, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/0001193125-22-118940-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}